- Home
- NHC vs KOD Comparison
NHC vs KOD Comparison
Compare NHC & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NHC | KOD |
|---|---|---|
| Founded | 1971 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.3B |
| IPO Year | 1997 | 2018 |
Fundamental Metrics
Financial Performance| Metric | NHC | KOD |
|---|---|---|
| Price | $157.70 | $42.70 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $35.43 |
| AVG Volume (30 Days) | 85.2K | ★ 1.3M |
| Earning Date | 05-08-2026 | 03-31-2026 |
| Dividend Yield | ★ 1.60% | N/A |
| EPS Growth | ★ 17.46 | N/A |
| EPS | ★ 7.67 | N/A |
| Revenue | ★ $1,517,781,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.79 | ★ N/A |
| Revenue Growth | ★ 16.09 | N/A |
| 52 Week Low | $89.14 | $1.92 |
| 52 Week High | $174.54 | $45.60 |
Technical Indicators
Market Signals| Indicator | NHC | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 46.65 | 72.36 |
| Support Level | $153.40 | $21.82 |
| Resistance Level | $171.47 | N/A |
| Average True Range (ATR) | 4.84 | 3.32 |
| MACD | -0.53 | 2.00 |
| Stochastic Oscillator | 30.36 | 88.15 |
Price Performance
Historical ComparisonAbout NHC National HealthCare Corporation
National Healthcare Corp provides long-term care facilities. Its principal business includes operating skilled nursing facilities, assisted living facilities, independent living facilities, and home care programs. The company's activities include providing sub-acute and post-acute skilled nursing care, intermediate nursing care, rehabilitative care, memory and Alzheimer's care, senior living services, and home health care services. In addition, the company also provides management services, accounting, and financial services, as well as insurance services to third-party operators of healthcare facilities. Its reportable segments include Inpatient services and Home care and hospice services. The majority of revenue is derived from the Inpatient services segment.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.